These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29956128)

  • 1. Inequality and Innovation: Barriers and Facilitators to 17P Administration to Prevent Preterm Birth among Medicaid Participants.
    Cross-Barnet C; Benatar S; Courtot B; Hill I; Johnston E; Cheeks M
    Matern Child Health J; 2018 Nov; 22(11):1607-1616. PubMed ID: 29956128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facilitators and Barriers to Healthy Pregnancy Spacing among Medicaid Beneficiaries: Findings from the National Strong Start Initiative.
    Cross-Barnet C; Courtot B; Hill I; Benatar S; Cheeks M; Markell J
    Womens Health Issues; 2018; 28(2):152-157. PubMed ID: 29339011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate.
    Lucas B; Poole-Yaeger A; Istwan N; Stanziano G; Rhea D; Mason M
    Am J Perinatol; 2012 Aug; 29(7):489-96. PubMed ID: 22399213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
    Mason MV; Poole-Yaeger A; Krueger CR; House KM; Lucas B
    Manag Care; 2010 Feb; 19(2):46-52. PubMed ID: 20550052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
    Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
    Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
    Sibai BM; Istwan NB; Palmer B; Stanziano GJ
    Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 17α-hydroxyprogesterone caproate access in the Louisiana Medicaid population.
    Orsulak MK; Block-Abraham D; Gee RE
    Clin Ther; 2015 Apr; 37(4):727-32. PubMed ID: 25700945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriate Use of Progesterone to Prevent Preterm Birth: Approaches to Measurement for Driving Improvement.
    Batra P; Hirai A; Selk S; Lee V; Lu M
    Matern Child Health J; 2017 Mar; 21(3):446-451. PubMed ID: 28092063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eligibility, Utilization, and Effectiveness of 17-Alpha Hydroxyprogesterone Caproate in a Statewide Population-Based Cohort of Medicaid Enrollees.
    Wang X; Garcia SM; Kellom KS; Boelig RC; Matone M
    Am J Perinatol; 2023 Dec; 40(16):1770-1780. PubMed ID: 34784617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
    Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
    Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice.
    Rebarber A; Fox NS; Klauser CK; Istwan NB; Rhea DJ; Stanziano GJ; Saltzman DH
    J Matern Fetal Neonatal Med; 2010 Oct; 23(10):1139-42. PubMed ID: 20170407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding barriers to uptake of 17 alpha-hydroxyprogesterone caproate (17-OHP) in women with history of preterm birth.
    Kalata M; Teter K; Wagner L; Swarr V; Witzeman K
    J Matern Fetal Neonatal Med; 2021 Feb; 34(4):541-546. PubMed ID: 31006296
    [No Abstract]   [Full Text] [Related]  

  • 13. 17-α hydroxyprogesterone caproate for the prevention of preterm birth.
    Gupta S; Roman AS
    Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17-α Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth: One Size May Not Fit All.
    Heyborne KD
    Obstet Gynecol; 2016 Oct; 128(4):899-903. PubMed ID: 27607880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What do women in Medicaid say about enhanced prenatal care? Findings from the national Strong Start evaluation.
    Hill I; Cross-Barnet C; Courtot B; Benatar S; Thornburgh S
    Birth; 2019 Jun; 46(2):244-252. PubMed ID: 31087393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
    Joy S; Rhea DJ; Istwan NB; Desch CN; Stanziano G
    Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in prematurity: what do changes at an urban institution suggest about the public health impact of 17-alpha hydroxyprogesterone caproate?
    Bastek JA; Adamczak JE; Hoffman S; Elovitz MA; Srinivas SK
    Matern Child Health J; 2012 Apr; 16(3):564-8. PubMed ID: 21484515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17 alpha-hydroxyprogesterone caproate (17P) usage in a Medicaid managed care plan and reduction in neonatal intensive care unit days.
    Mason MV; House KM; Fuest CM; Fitzgerald DR; Kitson BJ; Inglis JA
    Manag Care; 2005 Oct; 14(10):58-63. PubMed ID: 16277194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention.
    Manuck TA; Watkins WS; Moore B; Esplin MS; Varner MW; Jackson GM; Yandell M; Jorde L
    Am J Obstet Gynecol; 2014 Apr; 210(4):321.e1-321.e21. PubMed ID: 24594138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.